Infradiaphragmatic Hodgkin's disease

Area of Science:

• Oncology
• Hematology
• Clinical Medicine

Background:

• Hodgkin's disease staging is crucial for treatment and prognosis.
• Supradiaphragmatic and infradiaphragmatic disease presentation can differ.
• Understanding demographic and clinical variations is key for targeted therapies.

Purpose of the Study:

• To compare clinical characteristics and outcomes of early-stage infradiaphragmatic Hodgkin's disease versus supradiaphragmatic Hodgkin's disease.
• To evaluate treatment approaches and survival rates for both disease locations.

Main Methods:

• Retrospective analysis of 133 supradiaphragmatic and 11 infradiaphragmatic stage I and II Hodgkin's disease patients treated between 1968 and 1994.
• Comparison of patient demographics, symptoms, histologic subtypes, and treatment modalities.
• Survival analysis based on disease location and treatment received.

Main Results:

• Infradiaphragmatic Hodgkin's disease patients were more frequently male and older, with a higher incidence of systemic symptoms and specific histologic subtypes (mixed cellularity, lymphocyte predominance).
• Primary treatments included radiotherapy, polychemotherapy, or combined modalities.
• Ten out of eleven patients with infradiaphragmatic disease achieved complete response, with 5- and 10-year survival rates of 90% and 67.5%, respectively.

Conclusions:

• Early-stage infradiaphragmatic Hodgkin's disease presents with distinct demographic and clinical features compared to supradiaphragmatic disease.
• Despite differences in presentation, similar treatment strategies yield comparable survival outcomes for both early-stage infradiaphragmatic and supradiaphragmatic Hodgkin's disease.